A $2,499 ultrasound that fits in your coat pocket and can image every organ in the body. Jonathan Rothberg — who already sold two biotech companies — asked why ultrasound machines cost $100K when the computing power costs $10, then built the answer. Butterfly iQ is a genuine medical breakthrough: semiconductor-based imaging that replaces a room full of equipment. The stock dropped 90% from SPAC peak because selling to hospitals is slow and doctors are skeptical of anything new. But if Butterfly becomes the stethoscope of the 21st century, the current price will look absurd.
Founded
2011
HQ
Guilford, CT
Total Raised
$600M+ (SPAC in 2021)
Founder
Jonathan Rothberg
Status
Public (NYSE: BFLY) — market cap approximately $400 million (down from $5 billion SPAC peak)
Website
www.butterflynetwork.comTHE ORIGIN STORY
Jonathan Rothberg — a serial biotech entrepreneur who previously founded 454 Life Sciences (sold to Roche) and Ion Torrent (sold to Life Technologies for $725 million) — asked a simple question: why does an ultrasound machine cost $100,000 when a smartphone has more computing power? In 2011, he founded Butterfly Network to build an ultrasound-on-a-chip.
The breakthrough: replacing the traditional piezoelectric transducer (expensive, fragile, single-purpose) with a semiconductor chip that could image the entire body from one device. The iQ launched in 2018 at $1,999.
WHAT THEY ACTUALLY DO
Handheld, whole-body ultrasound device that connects to a smartphone. Traditional ultrasound machines cost $20,000-$200,000 and require trained technicians.
Butterfly iQ costs $2,499 and can be used by any clinician with basic training. Revenue comes from device sales and a SaaS subscription ($420/year for the Butterfly iQ+ cloud platform that stores images, enables AI analysis, and provides training).
The vision: make medical imaging as common as a stethoscope.
THE PRODUCTS
Butterfly iQ+ (handheld whole-body ultrasound device, $2,499), Butterfly iQ3 (latest generation with improved image quality), Butterfly Cloud (SaaS platform for image storage, AI analysis, and telemedicine), Butterfly Auto (AI-assisted image interpretation), and Butterfly Blueprint (training and education platform for ultrasound novices).
HOW THEY GREW
Point-of-care everywhere. Butterfly's strategy is to put an ultrasound in every clinician's pocket — not replacing radiology departments, but enabling imaging where it doesn't exist: rural clinics, ambulances, developing countries, home health visits.
The AI layer (Butterfly Auto) helps non-specialists interpret images. Partnerships with veterinary companies expand the addressable market.
The subscription model creates recurring revenue as the installed base grows.
THE HARD PART
Adoption. Doctors are creatures of habit — they've used traditional ultrasound for decades and are skeptical of a $2,499 handheld device.
The image quality, while impressive for the price, doesn't match a $100,000 cart-based system for complex diagnostics. Sales cycles in healthcare are notoriously slow.
The stock has dropped over 90% from its SPAC peak as revenue growth hasn't matched the hype. The device is a breakthrough, but turning a breakthrough into a business at scale is a different challenge.
MONEY TRAIL
Series D
2017 · Led by Fosun Pharma, Gates Foundation
$250M raised
SPAC
2021 · Led by Public via SPAC (Longview Acquisition Corp)
$589M raised
WHO BACKED THEM
Fosun Pharma, Bill & Melinda Gates Foundation, and various institutional investors backed Butterfly. Went public via SPAC in 2021.
Related Profiles
Head-to-Head
Compare Butterfly Network vs another company.